CoChat

Wilder's principle: pre-treatment value determines post-treatment response

Open access
Messerli, F. H., Bangalore, S., Schmieder, R. E. · 2015 · European Heart Journal
Cited by 90

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Over more than half a century numerous studies have documented that pre-treatment blood pressure (BP) is a determinant of the anti-hypertensive response.1–9 This has been shown for systolic and diastolic BP, acute and long-term response, monotherapy and combination therapy, and for office BP as well as for 24 h ambulatory BP. The first observation along that line was perhaps made by Freis et al. who, in 1958, in a very careful in-patient study reported a decrease in BP with chlorothiazide in every single hypertensive patient whereas in 15 normotensive subjects followed under exactly similar dietary and hospital control conditions, no reduction in BP occurred.10 This phenomenon that the pre-treatment level determines to a large extent the change per se, that is, the principle of initial value (German: Ausgangswertgesetz) was first described by Josef Wilder in 1931 who proposed that the ‘direction of response of body function to any agent depends to a large degree on the initial valuable of that function’.11,12 In 1976, Dixon and Johnson put forward the hypothesis that ‘the magnitude of the fall in blood-pressure in response to an antihypertensive drug depends on the level of the pretreatment pressure, and there is a direct relationship between the two in that the higher the pretreatment pressure the greater the fall in pressure in response to treatment’.13 Subsequent testing of this hypothesis in 42 published small studies in a total of 971 patients with 23 anti-hypertensive drug regimens revealed that in clinical practice ‘most of the regimens failed to show ideal behavior’ but that the ‘hypothesis of relating pretreatment BP to the subsequent fall in BP provided a useful method for assessing the effectiveness and variability of patient-responses to treatment’.14 Law et al., by doing a meta-analysis of 354 randomized double-blind, placebo-controlled trials of thiazides, β blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers, showed that the relation between the pre-treatment level and the fall in blood pressure (BP) was well fitted by a straight line.15 If pre-treatment BP was 10 mmHg higher, the reduction in BP with one drug at standard dose increased on average by 1.0 (95% confidence interval 0.7–1.2) mmHg systolic and 1.1 (0.8–1.4) mmHg diastolic.15 The observation that the pre-treatment value is a determinant of the post-treatment response is by no means restricted to hypertensive cardiovascular disease. A similar phenomenon has been observed for the therapeutic response of heart rate,16 haemoglobin A1c.17,18 total cholesterol, LDL and HDL cholesterol,19,20 and body mass index after LAP-BAND placement.21 It likely applies to most therapeutic responses that can be graded. The greater the baseline risk (up to a certain degree), the greater the magnitude of benefit from a therapy. Particularly, illustrative are the heart rate data with ivabradine (Figure 1) showing regardless of the dose employed an almost identical pattern of response entirely depending on pre-treatment values.16 The decrease in heart rate is very pronounced in patients with a resting heart rate >90, but below a pre-treatment heart rate of 60 the negative chronotropic effect of ivabradine seems to vanish. However, generalizations of Wilder's principle should be done cautiously. Berntson et al. showed that manipulations, which are known to be largely of autonomic origin, yielded larger effects than did manipulations having significant non-autonomic components.22 Wilder himself stated that beyond a certain medium range there was an increasing tendency toward absent and even toward reversed (paradoxic) responses.12 Baseline heart rate and heart rate response to three different doses of Ivabradine. Regression to the mean is defined as the phenomenon that an extreme variable of an individual on first measurement will tend to be closer to the mean on its second measurement. Thus, it is a purely statistical phenomenon that can be observed with any clinical parameter such as BP, heart rate, BMI, cholesterol, etc. With regression to the mean, the correction can be upward or downward. In contrast, Wilder's principle states that the mean response in a population depends on the mean pre-treatment value. In other words, the higher is the mean BP in a patient population at baseline the greater will be the decrease in BP with anti-hypertensive therapy. Thus, in RCT's regression to the mean is dealt with by design, and by the observed treatment effect in the placebo group, while the principle of initial value is not affected by study design. Little surprise that pharma has used these and other data for marketing purposes. The simple fact that response to a drug is more marked when pre-treatment levels are high and gradually diminishes as pre-treatment levels become lower seems to attest to its safety and efficacy. Such a drug has been touted to be ‘intelligent’ in that it lowers the endpoint prog

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu467

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 90

Metadata

Authors
Messerli, F. H., Bangalore, S., & Schmieder, R. E.
Venue
European Heart Journal
Published
2014-12-23
Volume
36
Issue
9
Pages
576-579
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2124872580
Cited by
90
References
2
FWCI
2.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Wilder's principle: pre-treatment value determines post-treatment response. https://app.cochat.ai/papers/10.1093/eurheartj/ehu467
The paper
Messerli, F. H., Bangalore, S., & Schmieder, R. E. (2015). Wilder's principle: pre-treatment value determines post-treatment response. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu467

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.